logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 13 of 13 Items
Showing 1 - 13 of 13 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Tuberculosis diagnosis and preventive monotherapy among children and adolescents exposed to rifampicin-resistant tuberculosis in the household

Apolisi I, Cox HS, Tyeku N, Daniels J, Mathee S,  et al.
2023-02-21 • Open Forum Infectious Diseases
2023-02-21 • Open Forum Infectious Diseases
BACKGROUND
Children and adolescents with household exposure to multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) are at high risk of developing TB disease. Tuberculosis pre...
Journal Article
|
Letter

Pediatric delamanid treatment for children with rifampicin-resistant TB

Tyeku N, Apolisi I, Daniels J, Beko B, Memani B,  et al.
2022-10-01 • International Journal of Tuberculosis and Lung Disease
2022-10-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Research

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

Boulle A, van Cutsem G, Cohen K, Hilderbrand K, Mathee S,  et al.
2008-08-06 • JAMA
2008-08-06 • JAMA
CONTEXT
Rifampicin-based antitubercular therapy reduces the plasma concentrations of nevirapine and efavirenz. The virological consequences of these interactions are not well describ...
Journal Article
|
Review

Cohort profile: the Khayelitsha antiretroviral programme, Cape Town, South Africa

Stinson K, Goemaere E, Coetzee D, van Cutsem G, Hilderbrand K,  et al.
2016-05-20 • International Journal of Epidemiology
2016-05-20 • International Journal of Epidemiology
Journal Article
|
Research

Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial

Rangaka MX, Wilkinson RJ, Boulle AM, Glynn JR, Fielding K,  et al.
2014-05-14 • Lancet
2014-05-14 • Lancet
Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid prevent...
Journal Article
|
Research

Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa

Boulle AM, van Cutsem G, Hilderbrand K, Cragg C, Abrahams M,  et al.
2010-02-20 • AIDS
2010-02-20 • AIDS
OBJECTIVES: We report on outcomes after 7 years of a community-based antiretroviral therapy (ART) programme in Khayelitsha, South Africa, with death registry linkages to correct for mort...
Journal Article
|
Research

Effect of Antiretroviral Therapy on the Diagnostic Accuracy of Symptom Screening for Intensified Tuberculosis Case Finding in a South African HIV clinic

Rangaka MX, Wilkinson RJ, Glynn JR, Boulle AM, van Cutsem G,  et al.
2012-09-05 • Clinical Infectious Diseases
2012-09-05 • Clinical Infectious Diseases
Current symptom screening algorithms for intensified tuberculosis case finding or prior to isoniazid preventive therapy (IPT) in patients infected with human immunodeficiency virus (HIV)...
Journal Article
|
Commentary

Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa

Apolisi I, Mema N, Tyeku N, Beko B, Memani B,  et al.
2022-03-01 • Lancet Respiratory Medicine
2022-03-01 • Lancet Respiratory Medicine
Journal Article
|
Research

Effectiveness of Patient Adherence Groups as a model of care for stable patients on Antiretroviral Therapy in Khayelitsha, Cape Town, South Africa

Luque Fernandez MA, van Cutsem G, Goemaere E, Hilderbrand K, Schomaker M,  et al.
2013-02-13 • PLOS One
2013-02-13 • PLOS One
Innovative models of care are required to cope with the ever-increasing number of patients on antiretroviral therapy in the most affected countries. This study, in Khayelitsha, South Afr...
Journal Article
|
Research

Correcting for Mortality Among Patients Lost to Follow Up on Antiretroviral Therapy in South Africa: A Cohort Analysis

van Cutsem G, Ford NP, Hilderbrand K, Goemaere E, Mathee S,  et al.
2011-02-17 • PLOS One
2011-02-17 • PLOS One
Loss to follow-up (LTF) challenges the reporting of antiretroviral treatment (ART) programmes, since it encompasses patients alive but lost to programme and deaths misclassified as LTF. ...
Journal Article
|
Letter

A home-based care programme for rifampicin-resistant TB

Douglas-Jones B, Mohr-Holland E, Mema N, Mathee S, Mathews G,  et al.
2021-07-01 • International Journal of Tuberculosis and Lung Disease
2021-07-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Commentary

Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic

Mohr-Holland E, Douglas-Jones B, Apolisi I, Ngambu N, Mathee S,  et al.
2021-03-01 • Lancet Child and Adolescent Health
2021-03-01 • Lancet Child and Adolescent Health
Journal Article
|
Commentary

Barriers and solutions to finding rifampicin-resistant tuberculosis cases in older children and adolescents

Mohr-Holland E, Apolisi I, Reuter A, De Azevedo V, Hill JE,  et al.
2019-12-21 • Public Health Action
2019-12-21 • Public Health Action
Little is known about the barriers to post-exposure management of rifampicin-resistant tuberculosis (RR-TB) in older children and adolescents. We report on implementation lessons from a ...